Table 1 Baseline characteristics of all participants at the time of biopsy collection and characteristics by skin and GI sample collection
|  | All participants (N = 19) | Skin KS participants* (N = 10) | GI KS participants* (N = 12) |
|---|---|---|---|
Age (median in years, IQR) | 37 (29, 46) | 43 (34, 49) | 30 (28.3, 36.1) |
Sex (n, %) | Â | Â | Â |
Cisgender Male | 17 (89) | 10 (100) | 10 (83) |
Cisgender Female | 1 (5) | Â | 1 (8) |
Transgender Female | 1 (5) | Â | 1 (8) |
Race (n, %) | Â | Â | Â |
White | 4 (21) | 2 (20) | 3 (25) |
Black | 10 (53) | 4 (40) | 7 (58) |
Hispanic | 5 (26) | 4 (40) | 2 (17) |
HIV characteristics | Â | Â | Â |
HIV co-infection (n, %) | 17 (89) | 9 (90) | 11 (92) |
Duration of HIV, median, (median in months, IQR) | 95 (5, 147) | 117 (5, 145) | 97 (26, 107) |
CD4 T-cell count, cells/µL (median, IQR) | 38 (24, 100) | 39 (19, 195) | 36 (25, 85) |
HIV viral load, copies/mL (median, IQR) | 443 (57, 5134) | 74 (39, 104) | 5134 (552, 47,759) |
On antiretroviral therapy (ART) at time of biopsy (n, % of HIV +) | 16 (94) | 10 (100) | 11 (92) |
KS characteristics | Â | Â | Â |
Duration of KS diagnosis (median in months, IQR) | 5 (0.9, 32) | 5 (1, 38) | 10 (1, 16) |
Prior therapy for KS or other KAD (n, %) | 7 (37) | 3 (30) | 6 (50) |
Concurrent KSHV-associated diseases (n, %) | Â | Â | Â |
None | 5 (16) | 5 (30) | 3 (8) |
KICS | 9 (53) | 3 (50) | 6 (58) |
MCD | 1 (11) | 1 (10) | Â |
PEL | 2 (11) | 1 (10) | 1 (8) |
MCD and PEL | 2 (11) | – | 2 (17) |
KSHV-VL, copies/106 PBMCs (median, IQR) | 377 (0, 1798) | 90 (0, 728) | 1148 (0, 2792) |